Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Leap Therapeutics, Inc. (LPTX : NSDQ)
 
 • Company Description   
Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

Number of Employees: 36

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.31 Daily Weekly Monthly
20 Day Moving Average: 891,230 shares
Shares Outstanding: 88.32 (millions)
Market Capitalization: $115.70 (millions)
Beta: 0.71
52 Week High: $4.17
52 Week Low: $0.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.39% 0.38%
12 Week -37.32% -31.99%
Year To Date -59.57% -51.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
47 THORNDIKE STREET SUITE B1-1
-
CAMBRIDGE,MA 02141
USA
ph: 617-714-0360
fax: -
ir@leaptx.com http://www.leaptx.com
 
 • General Corporate Information   
Officers
Douglas E. Onsi - Chief Executive Officer; President; Chief Financia
Christopher K. Mirabelli - Chairman
Monica M. Bertagnolli - Director
James Cavanaugh - Director
Thomas Dietz - Director

Peer Information
Leap Therapeutics, Inc. (CORR.)
Leap Therapeutics, Inc. (RSPI)
Leap Therapeutics, Inc. (CGXP)
Leap Therapeutics, Inc. (BGEN)
Leap Therapeutics, Inc. (GTBP)
Leap Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 52187K101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 88.32
Most Recent Split Date: (:1)
Beta: 0.71
Market Capitalization: $115.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.17
Price/Cash Flow: -
Price / Sales: 77.13
EPS Growth
vs. Year Ago Period: 25.00%
vs. Previous Quarter: 10.00%
Sales Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
ROE
03/31/22 - -47.38
12/31/21 - -55.42
09/30/21 - -63.02
ROA
03/31/22 - -42.92
12/31/21 - -49.24
09/30/21 - -54.86
Current Ratio
03/31/22 - 14.29
12/31/21 - 11.70
09/30/21 - 11.11
Quick Ratio
03/31/22 - -
12/31/21 - 11.70
09/30/21 - 11.11
Operating Margin
03/31/22 - -
12/31/21 - -2,705.80
09/30/21 - -2,433.93
Net Margin
03/31/22 - -
12/31/21 - -2,705.80
09/30/21 - -2,433.93
Pre-Tax Margin
03/31/22 - -3,720.27
12/31/21 - -2,707.40
09/30/21 - -2,434.07
Book Value
03/31/22 - 1.12
12/31/21 - 1.22
09/30/21 - 1.33
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©